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is known to be correlated with negative health outcomes in
pediatric primary care and subspecialties; it is not known
how poverty impacts HSCT outcomes.
Objective: To describe the baseline prevalence of poverty
and material hardship in the pediatric HSCT population at a
major referral center. To describe transplant-related work
disruptions and income losses stratiﬁed by federal poverty
level (FPL) in this patient population, and explore the rela-
tionship between family poverty and clinical outcomes.
Methods: Single institution, cross-sectional survey. Partici-
pants included 45 English-speaking, pediatric allogeneic
HSCT families whose children had undergone HSCT in the
prior twelve months and were alive at time of survey
administration. Eighty-seven percent of families approached
consented to study participation. This studywas approved by
the Dana-Farber Cancer Institute Institutional Review Board.
Results: Poverty prior to transplant was prevalent with 18
(40%) families reporting baseline incomes at or below 200%
FPL ($44,000 for a family of four). Parental work disruptions
due to HSCT were common across all income levels with 39
(87%) families reporting some disruption, and consequent
income losses were substantial for all families. Families at or
below 200% FPL were disproportionately impacted with 7
(39%) of the poorest families reporting transplant-associated
annual income losses of >40% as compared to 2 (18%) of the
wealthiest families (p¼0.006). Material hardship during the
post-transplant period was widespread, with 17 (38%) fam-
ilies reporting either food, housing, or energy insecurity.
Baseline family poverty level was not associated with length
of transplant admission, unplanned re-admissions, or ICU
stay in the 6-month post-transplant period in univariate
analysis. Poorer children, however, were more likely to
experience Graft Versus Host Disease (GVHD) of any grade in
the 6 month post-transplant period with eleven (61%) of
those at or below 200% FPL experiencing GVHD as compared
with 2 (18%) of the wealthiest (p¼0.01).
Conclusion: Baseline poverty is widely prevalent in the pe-
diatric HSCT population, and poverty may be associated with
the development of GVHD. Material hardship during the
post-transplant perioddincluding food, housing, or energy
insecuritydis widespread. Further studies aimed at under-
standing how these social determinants of health contribute
to HSCToutcomesmay provide targetable factors to decrease
transplant-associated morbidity and mortality.241
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Non-malignant hematologic disorders of childhood
comprise a number of various disorders including acquired
severe aplastic anemia (SAA), and inherited marrow failure
syndromes. Patients with such diseases who do not have
matched related donors fare poorly with allogeneic HSCT
from alternative donors and are at high risk for developing
chronic GvHD.We report 14 patients aged 0.7-18 years of age
(median 5.3 years) who received T-cell depleted HSCT fromalternative donors between April 2005 and May 2013. Dis-
eases included acquired SAA including PNH (N¼6), severe
chronic neutropenia (SCN)(N¼2), congenital amegakar-
yotycic thrombocytopenia (N¼2), Shwachman Diamond
syndrome (N¼1), autoimmune hemolytic anemia (N¼1),
chronic granulomatous disease (N¼1) and hemophagocytic
lymphohistiocytosis (N¼1). Two patients with SAA had
constitutional abnormalities and were therefore thought to
have possibly genetic diseases despite negative testing for
deﬁned disorders. Ten patients had long standing symp-
tomatic disease for> 1 year prior to transplant. Patients with
Fanconi anemia and dyskeratosis congenita were treated
with reduced intensity regimens and were not included.
Patients received one of 3 myeloablative regimens: Busulfan
Melphalan and Fludarabine (N¼2), Cyclophosphamide Thio
Flu (N¼3) or Mel, Thio Flu (N¼9). Patients received rabbit
ATG pre-transplant and ﬁlgrastim post transplant to promote
engraftment. Donors were unrelated HLA-matched donors
(N¼5), unrelated HLA-mismatched donors (N¼6) or related
HLA-mismatched donors (N¼2), and related phenotypic
matched donor (N¼1). Grafts included soybean agglutinin
negative, E-rosette negative bone marrow grafts (N¼5),
Isolex CD34+ E-rosette- peripheral blood stem cell grafts
(N ¼ 4), or CliniMACS CD34+ PBSC grafts (N¼5).
All 13 evaluable patients engrafted. Neutrophil engraftment
occurred on day +12 and platelet engraftment to 20,000 on
day +20 post transplant. Four patients died frommulti-organ
failure and/or infection (three of whom had a duration of
their disease of 2-7 years). One patient with SAA fully
engrafted with donor cells developed a pancytopenia post
transplant with secondary MDS in donor cells; this patient is
alive. Excluding one patient who is too early post transplant
and with a median follow-up of 2 years, 8 of 13 patients are
alive (OS 61%). None of these patients has evidence of GvHD.
These results should encourage proceeding to transplant
with chemotherapy-only cytoreductive regimens and T-cell
depleted stem cell transplants from alternative donors for
patients with nonmalignant hematologic disorders earlier in
the course of their disease.242
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Background: Hemophagocytic Lymphohistiocytosis (HLH) is
an immune regulatory disorder requiring allogeneic he-
matopoietic stem cell transfusion (HSCT) for long-term sur-
vival. More importantly, it is imperative to initiate treatment
early as delays in treatment can be associated with signiﬁ-
cant mortality. Unfortunately, there can be signiﬁcant over-
lap of the HLH diagnostic criteria with other non-HLH
conditions, thereby considerably delaying diagnosis and
therapy for HLH. Hence, surrogate markers are needed to aid
in the diagnosis and prevent delays in initiating therapy in
this life threatening disorder. Hypogammaglobulinemia has
been a less commonly reported feature of HLH. It has been
reported in SAP deﬁcient patients +/- HLH. More recently, it
has been reported in a few patients with XIAP deﬁciency and
STXBP2 mutations in association with colitis. We have
observed B-cell lymphopenia as well as hypogammaglobu-
linemia in patients with HLH at our institution. However, the
